anti-VEGF

anti-VEGF

anti-VEGF

Thrombotic microangiopathy and anti-VEGF agents

Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions

Hypertension as a surrogate marker for the activity of anti-VEGF agents

Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?

177PRadiologic feature after chemotherapy with anti-VEGF drug for CLM

What is the risk of intracranial bleeding during anti-VEGF therapy?

Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg)

Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA

Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma

Renal side effects of anti-VEGF therapy in man: a new test system*

L08.02NOV C-TER: A NOVEL VEGF-INDEPENDENT ANTI-ANGIOGENIC AGENT WITH A PROMISING PRECLINICAL ANTI-TUMOR EFFICACY

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension?

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer†

P-027Cancer stem cells marker CD44 and Notch activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies